Collplant Biotechnologies Ltd (CLGN : NASDAQ)
Common Stock
Follow CLGN
CLGN
Collplant Biotechnologies Ltd
Performance
1 Day
+0.00%
1 Week
-21.34%
1 Month
-5.93%
YTD
+8.31%
The Saturday TSX Wrap · free, every saturday morning. The week on the TSX, in five minutes.
Key Statistics
Market Cap
$14.27M
52W High
$22.50
52W Low
$2.64
P/E Ratio
-
50 Day MA
$3.84
200 Day MA
$4.14
Beta
0.57
Dividend Yield
-
Performance history
CLGN returns since 2026
Collplant Biotechnologies Ltd has traded since Jun 2026 in our data. Its deepest fall was −36.2% (Jul 2026 to Jul 2026).
1 year / yr
—
3 years / yr
—
5 years / yr
—
10 years / yr
—
Calendar-year returns
- 2026*+8.3%
* Partial year (first year of data, or year to date).
$10,000 invested in CLGN
- 2026 (start of our data)$10,831
- All-time high in our data
- $5 on Nov 12, 2026 · now −21.3%
Total-return basis using adjusted daily closes from the Toronto Stock Exchange and TSX Venture (dividends and splits folded in), Jun 2026 to Nov 2026. Past returns do not predict future ones.
Awesome Portfolio™
Looking past CLGN? Our 10 best Canadian stocks, in one list.
14.8% a year since 2017 against 9.7% for the S&P/TSX Composite (+5.0 points a year). Reviewed every month.
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/13/2026 | $4.10 | $4.28 | $3.60 | $3.65 | $3.65 | 73,778 |
| 11/12/2026 | $4.05 | $4.64 | $4.05 | $4.64 | $4.64 | 126,377 |
| 11/11/2026 | $4.03 | $4.20 | $3.86 | $3.96 | $3.96 | 25,053 |
| 11/10/2026 | $4.15 | $4.15 | $3.86 | $3.90 | $3.90 | 22,144 |
| 11/9/2026 | $4.00 | $4.29 | $3.76 | $4.29 | $4.29 | 23,990 |
| 11/6/2026 | $4.18 | $4.19 | $3.85 | $3.97 | $3.97 | 29,216 |
| 11/5/2026 | $4.13 | $4.25 | $3.94 | $3.94 | $3.94 | 100,468 |
| 11/4/2026 | $4.19 | $4.50 | $4.08 | $4.23 | $4.23 | 36,177 |
| 11/3/2026 | $4.01 | $4.44 | $3.99 | $4.11 | $4.11 | 22,969 |
| 11/2/2026 | $4.15 | $4.20 | $3.95 | $4.08 | $4.08 | 40,495 |
Analyst Price Targets
Based on analyst covering CLGN · as of Oct 5, 2026
Wall Street analysts forecast CLGN stock price to rise 204.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
US$11.12
+204.7% Upside
Current Price
US$3.65
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CLGN's historical volatility
30-Day Vol
132.6%
Annualized
90-Day Vol
112.6%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$4.36
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$3.87 | US$2.45 – US$6.12 |
| 60 trading days | US$4.11 | US$2.15 – US$7.85 |
| 90 trading days | US$4.36 | US$1.98 – US$9.64 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Collplant Biotechnologies Ltd
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a combinant human Collagen type I solution; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound care product for the treatment of deep surgical incisions and deep wounds. It also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. The company has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Financials
- Revenue (TTM)
- $318,000
- EBITDA
- $-11.56M
- Profit Margin
- 0.00%
- ROE (TTM)
- -161.98%
- EPS (Diluted)
- -9.33
- Book Value
- 2.04
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Free newsletter
The Saturday TSX Wrap
The week on the TSX, in five minutes
- The biggest gainers and losers, and why they moved
- Sector and momentum moves at a glance
- The Canadian market stories you missed
Explore More
Common Questions About CLGN.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| SEAT | Vivid Seats Inc | $2.09 | +63.28% |
| MRKR | Marker Therapeutics Inc | $1.32 | +54.71% |
| ELOG | Eastern International Ltd. | $1.45 | +46.46% |
| BAER | Bridger Aerospace Group Holdings, Inc. Common Stock | $0.31 | +45.64% |
| ZKIN | ZK International Group Co Ltd | $1.65 | +32.00% |
| FLD | Fold Holdings, Inc. Class A Common Stock | $0.29 | +27.19% |
| FISN | Deep Fission, Inc. Common Stock | $3.41 | +25.83% |
| ZEO | Zeo Energy Corp. | $0.29 | +24.09% |
Free with a Wealth Awesome account
Keep analysing CLGN, free
- Every WA Score, ranking and table
- Insider track records and SEDI filings
- Earnings history and analyst targets for every stock
Email only, no password, no card. Already a member? Use the same button to sign in.